These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
166 related items for PubMed ID: 9067284
21. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice. Rakhit A, Yeon MM, Ferrante J, Fettner S, Nadeau R, Motzer R, Bukowski R, Carvajal DM, Wilkinson VL, Presky DH, Magram J, Gately MK. Clin Pharmacol Ther; 1999 Jun; 65(6):615-29. PubMed ID: 10391667 [Abstract] [Full Text] [Related]
22. Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma. Suyama T, Furuya M, Nishiyama M, Kasuya Y, Kimura S, Ichikawa T, Ueda T, Nikaido T, Ito H, Ishikura H. Cancer; 2005 Jan 15; 103(2):258-67. PubMed ID: 15578685 [Abstract] [Full Text] [Related]
23. Proteome characterization of human NK-92 cells identifies novel IFN-alpha and IL-15 target genes. Rakkola R, Matikainen S, Nyman TA. J Proteome Res; 2005 Jan 15; 4(1):75-82. PubMed ID: 15707360 [Abstract] [Full Text] [Related]
27. Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka M, Su Z, Lebedeva IV, Kang D, Jiang H, Lin JJ, Alexandre D, Chen Y, Vozhilla N, Mei MX, Christiansen KA, Sivo F, Goldstein NI, Mhashilkar AB, Chada S, Huberman E, Pestka S, Fisher PB. Oncogene; 2001 Oct 25; 20(48):7051-63. PubMed ID: 11704829 [Abstract] [Full Text] [Related]
29. Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor. Sato A, Oya M, Ito K, Mizuno R, Horiguchi Y, Umezawa K, Hayakawa M, Murai M. Int J Oncol; 2006 Apr 25; 28(4):841-6. PubMed ID: 16525632 [Abstract] [Full Text] [Related]
31. Changes in gene expression during chemical-induced nephrocarcinogenicity in the Eker rat. Patel SK, Ma N, Monks TJ, Lau SS. Mol Carcinog; 2003 Nov 25; 38(3):141-54. PubMed ID: 14587099 [Abstract] [Full Text] [Related]
34. Suppression of human ribosomal protein L23A expression during cell growth inhibition by interferon-beta. Jiang H, Lin JJ, Tao J, Fisher PB. Oncogene; 1997 Jan 30; 14(4):473-80. PubMed ID: 9053844 [Abstract] [Full Text] [Related]
39. [Anti-neoplastic activity of a human recombinant tumor necrosis factor (Hu-rec-TNF) alone or in combination with human recombinant gamma-interferon, doxorubicin or cis-platinum on a human renal cell carcinoma line]. Gohji K, Hamami G, Kamidono S. Hinyokika Kiyo; 1987 Mar 30; 33(3):329-35. PubMed ID: 3113191 [Abstract] [Full Text] [Related]